5/6 Nephrectomy-induced Rat CKD Model

Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Non-GLP Toxicity Assessment Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Neurological Disease Efficacy Evaluation
In Vitro TestingBehavioral AnalysisIn Vivo Drug Efficacy EvaluationIn Vivo Biochemical ExaminingParkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Cell Therapy & Gene Therapy Efficacy Evaluation
Disease Rat Models
5/6 Nephrectomy-induced Rat CKD ModelCCL4-induced Chronic Liver Fibrosis Models in SD RatSTZ-induced Type I Diabetes Model in SD RatOVX-induced Rat Osteoporosis ModelMCAO-induced CIS Model in SD Rat2K1C-induced Hypertension Model in SD Rat

Chronic kidney failure, also known as chronic kidney disease (CKD), is a progressive and irreversible deterioration of kidney function over months or years. It results in the kidneys' inability to effectively filter waste, regulate electrolytes, maintain fluid balance, and produce essential hormones. At GemPharmatech, we offer validated models of CKD to meet your research needs.

5/6 nephrectomy-induced rat CKD model

The 5/6 nephrectomy model is a widely used experimental method to induce chronic kidney failure (CKD) in rats. By surgically removing 5/6 of the kidney mass, the remaining renal tissue undergoes hyperfiltration injury, leading to progressive glomerulosclerosis tubulointerstitial fibrosis, and renal dysfunction, mimicking human CKD progression.

 

11.png

Fig.1 Overview of pharmacodynamic evaluation on 5/6 nephrectomy-induced rat CKD model

 

 22.png

Fig.2 Body weight, urine biochemistry and blood pressure of 5/6 nephrectomy-induced rat CKD model


Body weight curve of 5/6 nephrectomy-induced rat CKD model is shown in Fig. 2A. The 24h-urine volume, urine MALB and CREA level were significantly higher in 5/6 nephrectomy-induced CKD rats compared to the control group(Fig. 2B-D). The SBP, DBP and MBP were significantly higher in 5/6 nephrectomy-induced CKD rats compared to the control group at W6(Fig. 2E). Data were presented by mean ± SEM, n=4-8. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001.

 

33.png

Fig.3 Kidney weight of 5/6 nephrectomy-induced rat CKD model


There is no significant difference in kidney weight between 5/6 nephrectomy-induced CKD rats compared to the control group. Data were presented by mean ± SEM, n=3. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001.

 

44.png

Fig.4 Histological observation of 5/6 nephrectomy-induced rat CKD model


Histopathological analysis of the rat kidney demonstrated marked renal injury, characterized by diffuse inflammatory infiltrates, pronounced tubular dilation and tubular necrosis, extensive interstitial fibrosis, and irregular GBM thickening in 5/6 nephrectomy-induced CKD rats at W9.

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.